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ABSTRACT
Three new findings are reviewed that help to understand the mechanisms of
action of antirheumatic Au(I) drugs, such as disodium aurothiomalate (Na2Au(I)TM):
(i) We found that Na2Au(I)TM selectively inhibits T cell receptor (TCR)-mediated
antigen recognition by murine CD4+ T cell hybridomas specific for antigenic pep-
tides containing at least two cysteine residues. Presumably, Au(I) acts as a chelating
agent forming linear complexes (Cys-Au(I)-Cys) which prevent correct antigen-
processing and/or peptide recognition by the TCR. (ii) We were able to show that
Au(I) is oxidized to Au(lll) in phagocytic cells, such as macrophages. Because Au(lll)
is re-reduced to Au(I) this may introduce an Au(I)/Au(lll) redox system into phago-
cytes which scavenges reactive oxygen species, such as OCI" and inactivates
lysosomal enzymes. (iii) Pretreatment with Au(lll) of a model protein antigen, bovine
ribonuclease A (RNase A), induced novel antigenic determinants recognized by
CD4+ T lymphocytes. Analysis of the fine specificity of these ’Au(lll)-specific’ T cells
revealed that they react to RNase peptides that are not presented to T cells when the
native protein, i.e., not treated with Au(lll), is used as antigen. The T cell recognition
of these cryptic peptides did not require the presence of gold. This finding has
important implications for understanding the pathogenesis of allergic and auto-
immune responses induced by Au(I) drugs. Taken together, our findings indicate that
Au(I) and Au(lll) each exert specific effects on several distinct components of
macrophages and the subsequent activation of T cells; these effects may explain
both the desired anti-inflammatory and the adverse effects of antirheumatic gold
drugs.
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The Antirheumatic Drug Gold, A Coin with Two Faces: A U(I) andA U(III).
Desired and Undesired Effects on the lmmune System
All antirheumatic gold drugs, such as disodium aurothiomalate (Na2Au(I)TM)
contain gold in the oxidation state +1. The mechanism of action of gold drugs is
unknown, but they are effective in the treatment of rheumatoid arthritis. With respect
to both their therapeutic and adverse effects gold drugs have been termed ’slow-
acting’ because there is a lag period of several weeks to months before they become
effective (1, 2). Eventually adverse immune reactions necessitate discontinuation of
gold therapy in up to one-third of patients (3-5). The immunopathologic alterations
developing under gold therapy (6) are summarized in Table 1. Although antirheu-
matic gold drugs have been successfully used for almost six decades, the mech-
anism of action underlying their beneficial and their adverse effects are still largely
unknown. This represents a challenge to both immunopharmacology and immuno-
toxicology. Here, we shall review recent results from our laboratory that help to
understand the mechanism of action of these compounds.
Table 1" Adverse immunologic side-effects of gold(I) drugs, such as
Na2Au(I)TM, and their genetic association
Pathological alterations Man Mouse
Dermatitis
Stomatitis
AIveolitis
Eosinophilia
Spleen and lymph node enlargement
IC glomerulonephritis
IgG and IgE increase
Antinuclear autoantibodies
Thrombopenia
Granulocytopenia
IgG and IgA decrease
Aplastic anemia
+
+
+
-I-
+
+
+
+
+
+
+
Genetic association"
MHC
Slow sulfoxidation status
Since many years it has been known that gold is stored and accumulated in
mononuclear phagocytes, especially their lysosomes or lysosome-like organelles (7-
10). In vitro, Au(I) can inhibit lysosomal enzymes, such as I-glucuronidase and acid
phosphatase .(11), which are known to participate in inflammatory reactions in the
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joints. In recent years, however, it has become clear that lysosomal proteases play a
crucial role in antigen-processing which takes place in lysosomes and related
organelles of antigen-presenting cells (APC) (cf. Fig. 1). The term ’antigen-process-
ing’ refers to the enzymatic cleavage of protein antigens into short peptides which
then can bind to MHC class II molecules. Subsequently, the peptide-MHC complexes
are transported to the surface of APC, where they are recognized by the T cell recep-
tor (TCR) of CD4+ T lymphocytes. It is important to know that APC cannot distin-
guish self proteins from foreign proteins so that they process both types of protein.
Because T cells are tolerant of or anergic to those self peptides that are efficiently
processed and presented, they fail to be activated by them.. By contrast, the presen-
tation of foreign peptides or self peptides not normally presented, i.e., cryptic pep-
tides, will activate T cells and thus trigger an immune response. In our view, the
accumulation and long-term storage of gold could well be relevant for its mechanism
of action. Any hypothesis trying to explain the mechanism of action of gold drugs
should try to incorporate the accumulation of gold in the lysosomes of phagocytic
cells.
GOLD KINETICS IN HUMANS AND MICE UNDER LONG-TERM TREATMENT WITH
Au(I) COMPOUNDS
Following the administration of antirheumatic Au(I) drugs to patients with
rheumatoid arthritis, numerous investigations, applying a variety of different tech-
niques, were undertaken to measure the concentration of gold in plasma and tissues
(reviewed in reference 12). It was consistently found that 80 90 % of the gold detect-
able in plasma is bound to serum albumin (13-15) and that gold accumulates in
kidney, liver, and spleen (16-20). Using morphological techniques for the examina-
tion of these organs, gold was found to be stored preferentially in lysosomes or
lysosome-like organelles of phagocytic cells (7-10). Ghadially (7), who used electron
X-ray analysis to describe such lysosomal bodies containing gold, introduced the
term ’aurosomes’ for these organelles. Other investigators who showed the uptake
and storage of gold in phagocytes used electron microscopy and autometallography,
respectively (10, 21, 22). In all these studies, however, gold concentrations were only
determined after cessation of treatment, never during ongoing treatment. Moreover,
if the kinetics of gold in the body were studied at all, these measurements were
confined to but a few organs and points in time.
As no systematic pharmacokinetic studies had been performed in animals or
men to determine gold tissue concentrations under chronic treatment, our group
performed such a study in mice using chronic treatment with Na2Au(I)TM and
atomic absorption spectrometry (AAS) (12). Mice of three different inbred strains,
A.SW, C57BL/6, and DBA/2, received weekly intramuscular injections of 22.5 mg
Na2Au(I)TM / kg body weight over a maximal period of 14 weeks. It should be noted
that the dosage used exceeds that given to rheumatoid arthritis patients by a factor
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of at least 30. This difference in dosage was chosen because of the greater metabolic
activity in mice compared to men and because previous investigations had shown
that this dosage induced immunologic side-effects in mice similar in those seen in
men (6, 23-25).
The results obtained by Tonn et al. (12) indicated that the tissue gold levels
showed significant differences both between strains and, in a time-dependent
manner, within a given strain and tissue, respectively. In all three tissues studied,
especially the spleen, strain DBA/2 contained lower gold levels than strains C57BL/6
and A.SW. Whereas the latter two strains are known to be susceptible to the adverse
immunologic side-effects of Na2Au(I)TM, strain DBA/2 is resistant (6, 23-25). An
observation made in all three mouse strains was that the concentration of gold in the
spleen, an organ of the immune system, steadily increased until week 10 or 12.
Throughout the observation period the resistant strain DBA/2 showed a lower
splenic gold concentration than the two susceptible mouse strains. Interestingly, of
the three splenic cell types studied, T and B cells of all three strains failed to contain
measurable concentrations of gold whereas splenic macrophages contained high
levels. Similarly, high levels of gold were detectable in peritoneal cells, known to be
rich in macrophages. These findings support the view (18, 21, 26) that the impair-
ment of lymphocyte activation induced by gold compounds (1, 27, 28) is due to an
effect of gold on accessory cells, such as macrophages, rather than to a direct effect
on lymphocytes (29).
The high gold concentration in macrophages is consistent with reports of
altered monocyte/macrophage functions resulting from exposure to gold salts in
vitro (30-33) and in vivo (34, 35). Severals authors (7, 9, 18, 21, 36) have described
the accumulation and storage of gold in lysosomes or lysosome-like cellular bodies
of macrophages, and it is conceivable that these organelles are the primary anatomi-
cal site of the pharmacologic and toxicologic action of gold drugs at the subcellular
level.
Au(I) INTERFERES WITH ANTIGEN-PROCESSING IN MACROPHAGES AND THE
PRESENTATION OF IMMUNOGENIC PEPTIDES CONTAINING TWO OR MORE
CYSTEINE RESIDUES
A number of findings suggest that the pharmacological mechanism of Au(I)
drugs directly or indirectly involves an effect on T lymphocytes. Na2Au(I)TM was
found to inhibit the proliferation of human T cells to IL-2 in vitro at concentrations
higher than 15 pM (27). Proliferation of human T cells induced by stimulation with
phorbol myristate acetate (PMA) and anti-CD3 monoclonal antibody (mAb) was
inhibited by Na2Au(I)TM concentrations higher than 30 IM (37). Na2Au(I)TM inhi-
bited protein kinase C (PKC) activity, but had no effect on the generation of inositol
1,4,5 trisphosphate (IP3) (37). These findings suggest that Na2Au(I)TM might
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suppress T cell activation by interfering with transmembrane signalling. Inhibition of
Concanavalin A (Con A)-induced T cell proliferation by Na2Au(I)TM, in contrast,
seemed to be mediated indirectly by an effect on the costimulatory capacity of
monocytes (29). An effect on MHC class II-bearing cells that can function as APC was
also implied by the observations that Au(I) bound to MHC molecules (38). These
results led to the hypothesis that gold might alter antigen presentation or T cell
recognition of presented MHC-peptide complexes (39).
Based on these findings we investigated the effect of Na2Au(I)TM on the
processing and presentation of protein antigens to T cells. Using a panel of murine
CD4+ T cell hybridomas specific for bovine RNase A, bovine insulin, hen egg
lysozyme, apamin, and cobra (Naja nigricollis) toxin, respectively, we demon-
strated that Na2Au(I)TM inhibited the interleukin-2 (IL-2) response of certain
hybridoma clones (P. Griem, K. Takahashi, H. Kalbacher and E. Gleichmann,
manuscript submitted). This effect was observed at Na2Au(I)TM concentrations that
were smaller than 10 pM and, thus, were not cytotoxic for T cells and were in the
same range as tissue gold concentrations of rheumatoid arthritis patients (20, 40),
which for instance reach 10- 50 pM in serum and about 10- 100 pM in synovial fluid.
The inhibition was not caused by a cytotoxic effect on the antigen presenting cells or
on the affected T-hybridoma cells. Disodium thiomalate alone had no effect on the T
cell reaction. Na2Au(I)TM affected only the antigen-induced but not the anti-CD3
monoclonal antibody-induced IL-2 release. We concluded that Au(I) could inhibit
activation of certain T cell clones by either interfering with antigen-processing or
interaction of the presented peptide-MHC complex with the TCR.
The T cell recognition of four peptides that contained two or more cysteine residues
could be inhibited by Na2Au(I)TM, whereas of five peptides with one or no cysteine
residue, only one peptide was weakly affected. Because Au(I) preferentially forms
linear complexes with two thiol ligands (20), we propose that Au(I) binds to free thiol
groups of the antigen. The binding of Au(I) to two thiol groups on the same peptide,
forming a chelate complex, should be much more stable than a ternary complex (41)
formed by one peptide thiol group, Au(I), and another thiol group, e.g. from free
cysteine or glutathione. Chelate complex formation could explain why the inhibitory
effect of Na2Au(I)TM requires the presence of two thiol groups in the antigenic
peptide. We propose that the observed inhibition of T cell activation by Na2Au(I)TM
might be mediated by binding of Au(I) to thiol groups of MHC-embedded peptides at
the cell surface or to partially processed antigen inside lysosomes, where Au(I) is
known to accumulate (12, 40, 42, 43). This complex formation might lead to steric
hindrance of TCR-MHC interaction or interference with further processing of antigen
and binding of antigenic peptides to MHC molecules.
The selective immunosuppressive effect of Na2Au(I)TM in vitro described
here might contribute to the beneficial effect of gold compounds in the treatment of
rheumatoid arthritis, because it matches the requirements (40) for rational
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explanation of clinical findings (26, 40, 44). The observed inter-patient variability of
the beneficial gold effect is not unexpected because remission should occur only
when the major arthritogenic peptide(s) contain(s) at least two cysteine residues,
which is unlikely to be the case in all patients. Intramolecular and intermolecular
determinant spreading (45) during the disease process may be responsible for the
fact that sustained benefit is rare and often variable over time. The slow onset of
clinical benefit during gold therapy could imply that it takes some time and a certain
tissue concentration before Au(I) can reduce the density of presented arthritogenic
peptides below the minimal density required for T cell activation (46). Finally, the
proposed selective effect of Au(I) drugs on certain peptides would be in line with the
lack of general immunosuppression during gold therapy (40, 47). Whether the pro-
posed mechanism really contributes to the therapeutic effect of Au(I) compounds in
rheumatoid arthritis will probably not be answered until the relevant autoantigens
are identified. It will then be possible to answer the question whether Au(I) drugs
have a greater beneficial effect in patients in which the major arthritiogenic peptides
contain two or more cysteine residues.
BIOOXIDATION OF Au(I) TO Au(lll) IN VIVO
At least some of the immunopathologic side-effects seen in man also develop
in susceptible mouse strains treated with weekly intramuscular injections of
Na2Au(I)TM (Table 1). Equimolar injections of the carrier disodium thiomalate
(Na2TM), by contrast, fail to induce any of these anormalities (6, 23, 48). As in
humans, genes linked to the MHC as well as non-MHC genes are involved in the
immunologic susceptibility of mice to Na2Au(I)TM (23). A strain-dependent suscepti-
bility to treatment with an Au(I) drug has also been demonstrated in rats. Brown
Norway rats developed an increased serum IgE level, proteinuria, and autoantibodies
to the glomerular basement membrane, whereas Lewis rats failed to do so (49).
Several lines of evidence suggest that T lymphocytes play a central role in the
development of immunopathologic reactions to gold(I) drugs (50). When this hypo-
thesis was tested in susceptible mouse strains (6), a perplexing result was obtained.
The gold(I) drug Na2Au(I)TM, although a potent inducer of adverse immune reac-
tions upon weekly intramuscular injections, failed to elicit the expected T cell reac-
tion in the direct popliteal lymph node assay (PLNA). By contrast, equimolar
amounts of Au(lll) salts readily induced a T cell-dependent PLN reaction. The PLNA is
an in vivo test system for measuring specific T cell reactions toward chemicals of
low molecular weight (6, 51-53).
To explain this discrepancy the hypothesis has been proposed that in vivo the
Au(I) of the slow-acting drug Na2Au(I)TM is gradually oxidized to Au(lll), and that it is
the latter which elicits T cell sensitization and thus initiates the GVH-like side-effects.
This was experimentally tested by Schuhmann et al. (6) using the adoptive transfer
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PLNA. The results of this experiment demonstrated that, indeed, weekly intra-
muscular injections of Au(I), given in the form of Na2Au(I)TM, sensitized T cells
neither to Au(I) nor to Na2TM but to Au(lll), even though the latter had never been
administered to the T cell donors.
In the adoptive transfer PLNA (6, 51-53) the test compound, such as
Na2Au(I)TM, is first administered to donor animals according to a schedule that is
relevant to human use of this compound. (In humans, Na2Au(I)TM is given by
repeated intramuscular injections.) Subsequently, T cells of the donor animals are
isolated from their spleens and injected subcutaneously into one hind foot pad of a
syngeneic recipient animal. The recipient serves merely as an indicator of reactivity
of the transferred T cells because, in addition to the donor T cells, the test compound
or one of its metabolites is injected into the same foot pad. As in the direct PLNA,
lymph node weight, cell number, or cell proliferation is measured 6 days later. By
means of this assay system it can be asked whether T cells of the donor animals
have been sensitized to the test compound or a metabolite. If in their new environ-
ment the donor T cells re-encounter the antigen to which they have been sensitized
previously, they mount a secondary immune response. The latter manifests itself by
quantitative and qualitative changes of lymphoid cells in the draining PLN of the
recipient. The dose of test antigen used in the adoptive transfer PLNA is always
below the minimal dose required for inducing a primary PLN response. Thus, a
primary PLN response of the recipient animal is avoided, but anamnestic responses
of the donor T cells transferred can be detected.
On the basis of their findings obtained with the adoptive transfer PLNA,
Schumann et al. (6) concluded that the adverse immune effects of Au(I) salts are in
fact caused by Au(lll) which must be generated in vivo through oxidation of Au(I). In
both animals and humans, gold is known to be accumulated and stored in the
lysosomes of monocytes and macrophages (7, 54, 55). Here, Au(I) might be oxidized
to Au(lll) by reactive oxygen species, such as HOCI (Fig. 1). In fact, in a cell-free
system in vitro, which contained the HOCI-generating factors H202, CI’, and
myeloperoxidase (MPO), Au(lll) was generated from Na2Au(I)TM (56; and paper by
C.F.Shaw III et al., this volume). Furthermore, Au(lll), other than Au(I), can irrevers-
ibly oxidize proteins (20, 57) and thus may be considered a reactive intermediate
metabolite. Altered self protein(s), in turn, if presented by MHC molecules on the
surface of macrophages, could elicit GVH-like reactions by T cells. In the presence of
protein, Au(lll) exists only for a few minutes (20, 58) because immediately after its
generation Au(lll) oxidizes proteins and is thus itself reduced to Au(I) again.
In the study of Schuhmann et al. (6) sensitized T cells were used as a probe to
detect alterations induced by Au(lll), a short-lived reactive intermediate metabolite
that in biological samples is not or is only detectable with difficulty by
physicochemical methods. Because T cells are known not to react to free metal Lons,
such as Au(lll), but react to MHC-embedded peptides (59), the observed T cell
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reactions cannot have been directed to Au(lll) itself, but to self protein(s)/peptide(s)
altered by this highly reactive heavy metal ion. In other words, the observed T cell
reactions presumably were not directed to the metabolite but to its footprints left on
self protein(s)/peptide(s) or on MHC molecules themselves (Fig. 1).
1) phagocytosis,
dominant
self-protein
MULTIPLE FUNCTIONS OF MONOCYTES/M
2) drug metabolism (ROS), 3) antigen presentation
proteases
T cell
tolerant
gold(I)
ROS(HOCI)
gold(Ill)
antigen TCR
T cell
immune
Figure 1. Monocytes and macrophages are involved in the formation of reactive drug
metabolites which than may interfer with the physiological presentation of self
proteins. The upper part of the figure shows the processing and presentation of a
self protein. Like microorganisms that have invaded the body, self proteins are taken
up by macrophages. The proteins are partially degraded into peptides by lysosomal
proteases. Of the peptides generated the ones that bind best to MHC class II mol-
ecules are transported to the cell surface, where the peptide-MHC complexes are
presented to T cells that recognize these with their T cell receptor (TCR). Only certain
peptides (termed dominant peptides) are efficiently cut out from the protein and pre-
sented on the cell surface. Due to the induction of tolerance during T cell develop-
ment, presentation of these peptides does not lead to T cell activation. The lower
part of the figure shows the oxidation of Au(I) to Au(lll) by reactive oxygen species
(ROS), like hypochloric acid (HOCI), in the lysosomal compartment. Oxidation of the
self protein by the reactive intermediate metabolite Au(lll) may induce an alteration
in its processing leading to the presentation of peptides that are not normally pre-
sented (termed cryptic peptides). Since these peptides are new to the immune
system, no T cell tolerance to them exists and an immune response is initiated.
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THE BIOOXIDATION OF Au(I) TO Au(lll) TAKES PLACE IN PHAGOCYTIC CELLS
Recently our group was able to provide direct experimental evidence for the
concept (Fig. 1) that biooxidation of Au(I) to Au(lll) takes place in phagocytic cells,
such as monocytes and macrophages. T cells of mice were primed to Au(lll) either by
weekly intramuscular injections of Au(I) in the form of Na2Au(I)TM, or by three
subcutaneous injections of HAu(III)CI4. Using the adoptive transfer PLNA, the trans-
ferred T cells of these animals were found to react in an anamnestic fashion not only
to the Au(lll) salt, but also to homogenized macrophages pretreated with
Na2Au(I)TM. The macrophages used were either activated syngeneic macrophages
that had been incubated with Na2Au(I)TM in vitro or peritoneal cells obtained from
syngeneic donors that had received weekly intramuscular injections of Na2Au(I)TM
for 12 weeks (C. Goebel, M. Kubicka-Muranyi, T. Tonn, J. Gonzalez, and E.
Gleichmann, manuscript submitted).
In humans who had been treated with Au(I) drugs for rheumatoid arthritis and
had subsequently developed dermatitits, anamnestic T cells responses to Au(lll)
were also observed (39, 60, 61; and T. Tonn, unpublished results). Verwilghen et al.
(61) tested peripheral blood lymphocytes of 17 patients with acute gold dermatitis in
the lymphocyte transformation test in vitro, and found that the cells of 13 of them
reacted to Au(lll), but not to Na2Au(I)TM or other heavy metal salts.
While the results of Verwilghen et al. (61) clearly reflect the differential
immunogenicity of Au(I) and Au(lll) salts and thus confirm in humans the findings
obtained in mice (6), the picture is not quite as clearcut in all investigations. In a few
patients a positive reaction to both Au(lll) and Au(I) was observed (T. Tonn,
unpublished results). Here, it can be argued that the putative reaction to Au(i) was in
fact directed towards Au(lll) that was generated by monocytes through oxidation of
Au(I) during the 1-week culture period. This explanation, however, can only be
applied with difficulty to the findings of Romagnoli et al. (39). They found that two T
cell clones obtained from the same patient reacted to both Au(I) and Au(lll) even
when the antigen-presenting cells (Epstein-Barr virus-transformed autologous B
cells) were glutaraldehyde-fixed. It is generally agreed that glutaraldehyde fixation
inactivates enzyme activities in cells (62, 63); if true, this would also pertain to the
enzymes involved in the oxidation of Au(I) to Au(lll). A possible explanation for the
inability of the two cell clones to distinguish between Au(I) and Au(lll) could be that
the Au(I) salt induces a conformational change of MHC class II molecules (64).
Conceivably, the two T cell clones studied by Romagnoli et al. (39) were specific for
class II molecules thus changed. Because Au(lll)is rapidly reduced to Au(I) by
protein, it may have caused identical reactions as Au(I) in this particular case.
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Bovine RNase A
Figure 2. Dominant and cryptic peptides of bovine ribonuclease A (RNase A).
Immunization of C57BL/6 mice with native RNase A leads to activation of T cells that
are specific for peptide 74-88. When mice were immunized with RNase A that had
been oxidized with Au(lll) (58), additional T cell specificities were found. T cell clones
that reacted to RNase/Au(lll) but not to native RNase, were found to be specific for
peptide 7-21 or peptide 94-108. Au(lll) addition was not required for the recognition
of the peptides but alteration of the protein by Au(lll) was necessary for efficient
cleavage of these peptides from the protein during antigen-processing.
Au(lll) INDUCES THE PRESENTATION OF CRYPTIC PEPTIDES
As the self proteins altered by Au(lll) have not yet been identified, we used
bovine RNase A as a model antigen and oxidized it by pretreatment with Au(lll) at
pH 2, as described by Isab and Sadler (58). Mice were immunized against
RNase/Au(lll), and CD4+ T cell hybridomas specifically recognizing RNase/Au(lll), but
not native RNase, were established (P. Griem, K. Beyer, and E. Gleichmann,
manuscript submitted). By using a set of overlapping peptides of bovine RNase A,
each 15 amino acids long, we were able to identify two peptides recognized by these
T cell hybridomas (Fig. 2). These peptides are not presented when APC are pulsed
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with native RNase, but only after pulsing them with RNase/Au(lll). Moreover, the
presence of gold was not necessary for the regognition of these peptides by the
RNase/Au(lll)-specific T cell clones. Hence, denaturing RNase by Au(lll) led to presen-
tation of cryptic peptides of bovine RNase A. Conceivably, the same happens with
self protein exposed to Au(lll) leading to the presentation of cryptic self peptides. By
definition, T cells fail to be tolerant to cryptic self peptides so that adverse immune
reactions may develop.
Au(I)/Au(lll) redox system:
1) Au(I)
Au(I) is phagocytosed and Induces
ROS in phagolysosomes
Au(III)
RO$, such as HOGI,
have been scavenged
2) Au(lll)
native protein
Au(I)
protein denatured by Au(lll)
ANTI-INFLAMMATORY EFFECTS
-scavenges ROS
-inactivates thiol-containlng lysosomal
enzymes
-chelates arthritogenic peptides containing
two or more cysteines and thus blocks
their recognition by TCR
ADVERSE EFFECTS
-possibly creates new epitopes on
self-proteins by the chelating effect
-denatures lysosomal proteins, such as
elastase and MPO
-denatures arthritogenic peptides and/or
MHC II molecules
-denatures self-proteins and thus leads to
presentation by MHC II molecules of cryptic
peptldes that activate specific CD4+ T cells
Figure 3. Hypothetical mechanisms for anti-inflammatory and adverse effects of Au(I)
and Au(lll).
Arguments for phagocytic cells as potential sites for the generation of reactive
drug metabolites (66) were summarized above. Regarding the actual immunogenicity
of drug metabolites thus generated, the findings obtained with Au(I)/Au(lll) were the
first to give experimental support to this important concept. Au(lll), however, is a
somewhat unusual intermediate whose generation in the body has been demon-
strated only in the indirect fashion outlined above. In contrast, the production by
phagocytes of reactive metabolites of procainamide (66-69) is generally accepted.
Therefore, we recently started to perform similar experiments with procainamide
and its reactive metabolites using the same experimental approach as with
Au(I)/Au(lll).
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POSSIBLE IMPLICATIONS OF THE BIOOXIDATION OF Au(I) TO Au(lll)
Generation of the highly reactive intermediate Au(lll) could also be relevant
with respect to the unknown pharmacological mechanism of action of Au(I) drugs.
Three anti-inflammatory mechanisms of Au(lll) may be envisaged (Fig. 3). Firstly, the
generation in phagocytic cells of Au(lll) from Au(I) scavenges reactive oxygen
species. Secondly, as already mentioned, Au(lll) is a highly reactive chemical that
irreversibly denatures protein (57). The candidate proteins to be denatured by Au(lll)
are those nearest to the site of oxidation of Au(I) to Au(lll). Presumably these are the
proteins located in the phago-lysosomes of phagocytic cells (60, 65), such as
iysosomal enzymes, which are known to enhance inflammation when released from
cells. Thirdly, Au(lll) may interfere with those lysosomal enzymes involved in
antigen-processing or may directly alter MHC molecules. Both mechanisms could
result in reduced production or presentation of arthritogenic (self) peptides. These
anti-inflammatory effects of gold should be enhanced and prolonged by the fact that
Au(lll) is very short-lived in the presence of protein because it rapidly oxidizes
protein and is re-reduced to Au(I) (20, 58). In fact, as pointed out by C.F. Shaw III
(personal communication, 1991), on the basis of the findings of Schuhmann et al. (6)
gold therapy may introduce a Au(I)/Au(lll) redox system into phagocytic cells (Fig. 3).
If this view is correct, the three anti-inflammatory actions of Au(I)/Au(lll) described
above would be effective over a prolonged period of time.
ACKNOWLEDGEMENTS
We thank E. Tosse GmbH and Company,.,., (Hamburg, Germany) for a gift of
aurothiomalic acid in the form of Tauredonw’.
REFERENCES
2.
3.
4.
5.
6.
Dillard, C. J. & Tappel, A. L. (1986) Med. Hypotheses 20, 407-420.
Lipsky, P. E. (1984) Alents Actions Suppl. 14, 181-204.
Davis, P. (1979) J. Rheumatol. 6, 18-23.
Gran, J. T., Husby G. & Thorsby, E. (1983) Ann. Rheum. Dis. 42, 63-71.
Lockie, L. M. & Smith, D. M. (1985) Sem. Arthritis Rheum. 14, 238-246.
Schuhmann, D., Kubicka-Muranyi, M., Mirtscheva, J., GLinther, J., Kind, P. &
Gleichmann, E. (1990) J. Immunol. 145, 2132-2139.
Ghadially, F. N. (1979) ,J". Rheumatol. 6, 45-50.
Gottlieb, N. L., Smith, P. M. & Smith, E. M. (1972) Arthritis Rheum. 15, 16.
Graudal, H., M611er-Madsen, B. & Danscher, G. (1988) Z. Rheumatol. 47, 347-
350.
Danscher, G., Hansen, H. J. & M6ller-Madsen, B. (1984) Histochemistry 81,283-
285.
Lee, M. T., Ahmed, T., Haddad, R. & Friedman, M. E. (1989) J. Enzym. Inhib. 3,
35-47.
Tonn, T., Goebel, C., Wilhelm, M. & Gleichmann, E. (1994) Br. J. Rheumatol. 33,
724-730.
494K. Takahashi, P. Griem, C. Goebel, J. Gonzalez and E. Gleichmann Metal BasedDrugs
13.
14.
15.
16.
17.
18.
19.
29.
30.
31.
32.
38.
39.
40.
McQueen, E. G. & Dykes, P. W. (1994) Ann. Rheum. Dis. 28, 437.
Danpure, C. J., Fyfe, D. A. & Gumpel, J.’ ’M. (’i979) Ahn’ Rheum. Dis. 38, 364.
Egila, J., Littlejohn, D., Smith, W. E. & Sturrock, R. D. (1992) J. Pharm. Biomed.
Anal. 10, 639-644.
Swartz, H. A., Christian, J. E. & Andrews, F. N. (1960) Am. J. Physiol. 199, 67.
Sugawa-Katayama, Y., Koishi, H. & Danbara, H. (1975) J. Nutrition 104, 957.
Sharma, R. P. & McQueen, E. G. (1979) Clin. Exp. Pharmacol. Physiol. 6, 561.
Lewis, A. J. & Walz, D. T. (1982) in P..r..og.ress in medicinal chemistry, eds. Ellis,
G. P. & West, G. B. (Elsevier Biomedical Press, New York), pp. 1-58
Shaw, C. F. (1979)!.nor..9. Perspect. Biol. Med. 2, 287-355.
Lawson, K. J., Danpure, C. J. & Fyfe, D. A. (1977) Biochem. Pharmacol. 26,
2417-2426.
MSIler-Madsen, B., Mogensen, S. C. & Danscher, G. (1984) Exp. Mol. Pathol. 40,
148-154.
Robinson, C. J. G., Balazs, T. & Egorov, I. K. (1986) Toxicol. Appl. Pharmacol.
86, 159-169.
Mirtscheva, J., Hallmann, B., Stark, M. & Gleichmann, E. (1986) Arch.
Pharmacol. 334, 171.
Pietsch, P., Vohr, H. W., Degitz, K. & Gleichmann, E. (1989) Int. Arch. Allergy
Appl. Immunol. 90, 47-53.
Kavanaugh, A. F. & Lipsky, P. E. (1992) in Inflammation, eds. Gallin, J. I.,
Goldstein, I. M. & Snyderman, R. (Raven Press, New York), pp. 1083-1101.
Wolf, R. E. & Hall, V. C. (1988) Arthritis Rheum. 31, 176-181.
Hashimoto, K., Whithurst, C. E., Matsubara, T., Hirohata, K. & Lipsky, P. E.
(1992) J. Clin. Invest. 89, 1839-1848.
Lipsky, P. E. & Ziff, M. (1977) J. Clin. Invest. 59, 455-466.
Littman, B. H. & Hall, R. E. (1985) Arthritis Rheum. 28, 1384-1392.
Ugai, K., Ziff, M. & Lipsky, P. E. (1979) Arthritis Rheum. 22, 1352-1360.
Scheinberg, Mo A., Santos, L. M. B. & Finkelstein, A. E. (1982) J. Rheumatol. 9,
366-369.
Seitz, M., Dewald, B., Ceska, M., Gerber, N. & Baggiolini, M. (1992) Rheumatol.
Int. 12, 159-164.
Farahat, M. N. M. R., Yanni, G., Poston, R. & Panayi, G. S. (1992) EULAR
Conlress Reports 1, 8.
Laib, J. E., Shaw, C. F., Petering, D. H., Eidsness, M. K., Elder, R. C. & Garvey, J.
S. (1985) Biochemistry 24, 1977-1986.
Christensen, M. M., Danscher, G., Ellermann Eriksen, S., Schionning, J. D. &
Rungby, J. (1992) Histochemistry.... 97, 207-211.
Hashimoto, K., Whitehurst, C. E. & Lipsky, P. E. (1994) J. Rheumatol. 21, 1020-
1026.
Sinigaglia, F. (1994) J. Invest. Dermatol. 102, 398-401.
Romagnoli, P., Spinas, G. A. & Sinigaglia, F. (1992) J. Clin. Invest. 89, 254-258.
Champion, G. D., Graham, G. G. & Ziegler, J. B. (190) Baillieres. Clin.
Rheumatol. 4, 491-534.
Shaw, C. F. (1989) Comments Inor. Chem. 8, 233-267.
M611er-Madsen, B., Morgensen, S. C. & Danscher, G. (1984) Exp. Mol. Pathol.
40, 148-154.
495Vol. 1, Nos. 5-6, 1994
56.
57.
58.
59.
60.
The Antirheumatic Drug Gold, A Coin with Two Faces: A U(I) andA UII).
Desired and Undesired Effects on the Immune System
Elder, R. C., Eidsness, M. K., Heeg, M. J., Tepperman, K. G., Shaw, C. F. &
Schaeffer, N. (1983) ACS Symposium Series. 209, 385-400.
Cash, J. M. & Klippel, J. H. (1994) N. Engl. J. Med. 330, 1368-1375.
Kaufman, D. L., Clare Salzler, M., Tian, J. D., Forsthuber, T., Ting, G. S. P.,
Robinson, P., Atkinson, M. A., Sercarz, E. E., Tobin, A. J. & Lehmann, P. V.
(1993) Nature 366, 69-72.
Harding, C. V. & Unanue, E. R. (1990) Nature 346, 574-576.
Lipsky, P. E. (1988) in Inflammation: Basic Principles and Clinical Correlates,
eds. Gallin, J. I., Goldstein, I. M. & Snyderman, R. (Raven Press, Ltd., New
York), pp. 897-910.
Cush, J. J., Lipsky, P. E., Postlethwaite, A. E., Schrohenloher, R. E., Saway, A. &
Koopman, W. J. (1990) Arthritis Rheum. 33, 19-28.
Tournade, H., Guery, J.’ C.,""’Pasquier, R., Nochy, D., Hinglais, N., Guilbert, B.,
Druet, P. & Pelletier, L. (1991) Nephrol. Dial. Transplant. 6, 621-630.
Gleichmann, E., Pals, S. T., Rc;"i’ink, A. G., Radaszkiewicz, T. & Gleichmann, H.
(1984) Immunol. Today 5, 324-332o
Gleichmann, E., Kind, P., Schuppe, H. C. & Merk, H. (1990) in Immunotoxicity of
Metals and ImmunotoxicololY, eds. Dayan, A. D., Hertel, R. F., Heseltine, E.,
Kazantzis, G., Smith, E. M. & Van der Venne, M. T. (Plenum Press, New York),
pp. 139-152.
Klinkhammer, C., Popowa, P. & Gleichmann, H. (1988) Diabetes 37, 74-80.
Kubicka-Muranyi, M., Behmer, O., Uhrberg, M., Klonows’ki, H’’Bister, J. &
Gleichmann, E. (1993)Int. J. Immunopharmacol. 15, 151-161.
Brown, D. H. & Smith, W. E.’ (1980)"Chem."Soc. Rev. 2, 217-241.
Jakobson, E., Andreasen, A., Graud’al, H. & Danscher, G. (1989) Scand. J.
Rheumatol. 18, 161-164.
Beverly, B. & Couri, D. (1987) Fed. Proc. 46, 854.
Witkiewicz, P. & Shaw, C. F. (’9’8’) J. C. S. Res. Comm. 1111-1114.
Isab, A. A. & Sadler, P. J. (1977) Biochim. Bi’0phys. Acta 492, 322-330.
Rothbard, J. B. & Gefter, M. L. (1991) Annu. Rev. Immunol. 9, 527-565.
Gleichmann, E., Kubicka-Muranyi, M., Kind, P., Goldermann, R., Goerz, G.,
Merk, H. & Rau, R. (1991) Rheumatol. Int. 11, 219-220.
Verwilghen, J., Kingsley, G. H., Gambling, L. & Panayi, G. S. (1992) Arthritis
Rheum. 35, 1413-1418.
Dlovitch, T. L., Semple, J. W. & Philips, M. L. (1988) Immunol.... Today 9, 216-
219.
Shimonkevitz, R., Kappler, J., Marrack, P. & Grey, H. (1983) J. Exp.. Med. 158,
303-316.
Sinigaglia, F., Takacs, B. & Romagnoli, P. (1992) Abstracts of the 8th Int. Congr.
Immunol., Budapest 619.
Gleichmann, E., Kubicka-Muranyi, M., Griem, P. & Goebel, C. (1992) Br. J.
Rheumatol. 31, 45.
Uetrecht, J. P. (1992) Drug Metabolism Rev. 24, 299-366.
Rubin, R. L. (1989) in .Autoimmu.nity an’d..T0xicololy, eds. Kammiller, M. E.,
Bloksma, N. & Seinen, W. (Elsevier Science, Amsterdam), pp. 119-150.
Uetrecht, J. P. (1988) Chem. Res. Toxicol. 1, 133-143.
Kubicka-Muranyi, M.,’ ’Goebels, R., G0ebel, C., Uetrecht, J. & Gleichmann, E.
(1993) Toxicol. App.I.P.harmacol. 122, 88-94.
496